# US 2004/0024039 A1 · Imidazole derivatives, process for their preparation and their use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0024039 A1
- Document ID: US20040024039A1
- Status: Published application
- Kind: A1
- Application number: 10/416,998
- Filed: 2003-05-16
- Published: 2004-02-05
- Earliest claimed: 2000-11-20
- Assignees: Takeda Pharmaceutical Company Limited
- Inventors: Akihiro Tasaka; Nobuyuki Matsunaga; Akio Ojida; Masami Kusaka
- Web page: https://patentgrep.com/patent/US20040024039A1

## CPC

- C07D 403/06: linked by a carbon chain containing only aliphatic carbon atoms
- A61P 13/08: of the prostate
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- Y02P 20/55: Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02P: CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS

## Abstract

The present invention provides a compound having a steroid C17,20-lyase inhibitory activity, which is useful as a prophylactic or therapeutic agent of prostatism and tumor such as breast cancer and the like. A compound represented by the formula: 1 wherein R is a hydrogen atom or a protecting group, R1 is a lower alkyl group or a cyclic alkyl group, and ring A and ring B are each an optionally substituted 5-membered or 6-membered ring having an amide bond in the ring, or a salt thereof.

## Claims

### Claim 1

A compound represented by the formula:
76
wherein R is a hydrogen atom or a protecting group, R1 is a lower alkyl group or a cyclic alkyl group, and ring A and ring B are each an optionally substituted 5-membered or 6-membered ring having an amide bond in the ring, or a salt thereof.

### Claim 2 (depends on 1)

The compound of claim 1, wherein the ring A and ring B are each represented by the formula:
77
wherein R2 is a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted amino group, and a dotted line indicates a single bond or a double bond when R2 is a hydrogen atom, a single bond when R2 is an optionally substituted hydrocarbon group or an optionally substituted amino group.

### Claim 3

A compound represented by the formula:
78
wherein R is a hydrogen atom or a protecting group, R1 is a lower alkyl group or a cyclic alkyl group, and R2 is a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted amino group, or a salt thereof.

### Claim 4

A prodrug of a compound represented by the formula (Ia) or (Ib)
79
wherein R is a hydrogen atom or a protecting group, R1 is a lower alkyl group or a cyclic alkyl group, and ring A and ring B are each an optionally substituted 5-membered or 6-membered ring having an amide bond in the ring, or a salt thereof.

### Claim 5

A pharmaceutical composition comprising a compound represented by the formula (Ia) or (Ib)
80
wherein R is a hydrogen atom or a protecting group, R1 is a lower alkyl group or a cyclic alkyl group, and ring A and ring B are each an optionally substituted 5-membered or 6-membered ring having an amide bond in the ring, or a salt thereof or a prodrug thereof.

### Claim 6 (depends on 5)

The composition of claim 5, which is a steroid C17,20-lyase inhibitor.

### Claim 7 (depends on 5)

The composition of claim 5, which is an antitumor agent.

### Claim 8 (depends on 5)

The composition of claim 5, which is an agent for the prophylaxis or treatment of breast cancer or prostate cancer.

### Claim 9

An androgen reducer comprising a compound represented by the formula (Ia) or (Ib)
81
wherein R is a hydrogen atom or a protecting group, R1 is a lower alkyl group or a cyclic alkyl group, and ring A and ring B are each an optionally substituted 5-membered or 6-membered ring having an amide bond in the ring, or a salt thereof or a prodrug thereof, and an LHRH modulator in combination.

### Claim 10

A production method of a compound represented by the formula:
82
wherein R is a hydrogen atom or a protecting group, and R1 is a lower alkyl group or a cyclic alkyl group, or a salt thereof, which comprises reacting a compound represented by the formula:
83
with a compound represented by the formula:
84
wherein each symbol is as defined above, or a salt thereof, in the presence of a base.
